Good article on Bloomberg today around big pharma/biotech buyouts and takeovers;
https://www.bloomberg.com/opinion/articles/2019-12-16/amarin-fish-oil-heart-drug-good-news-is-already-priced-in-stock?srnd=premium-asia
Relates to a bio-pharmaceutical company (Amarin) that's managed to patent a fish oil supplement (Vascepa) in pill form as a heart attack and stroke preventative.
Interesting points around restricted FDA approval, and a comment that insurance reimbursal wasn't assured, despite the low cost, because of the numbers of people likely to be taking it.
research reports and media, page-380
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.010(4.08%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 23.3¢ | $73.22K | 308.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 49081 | 6 |
View Market Depth
| Last trade - 15.02pm 02/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |